Search for content and authors
 

SYNTHESIS, CRYSTAL STRUCTURE AND BIOLOGICAL ACTIVITY OF COPPER (II) COMPLEXES WITH CHELATING BIDENTATE 2-SUBSTITUTED BENZIMIDAZOLE LIGANDS.

Ewa Dziemidowicz-Borys 1,3Franciszek Sączewski 1Maria Gdaniec 2Patrick J. Bednarski 3

1. Medical University of Gdańsk, Department of Chemical Technology of Drugs, Al. Gen. J. Hallera 107, Gdańsk 80-416, Poland
2. Adam Mickiewicz University, Faculty of Chemistry, Grunwaldzka 6, Poznań 60-780, Poland
3. University of Greifswald, Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Greifswald D-17487, Germany

Abstract

Complexes based on copper have demonstrated various biological activities and are among the most potent antivirial, antitumor and antiinflammatory agents. Anticancer copper (II) complexes synthesized recently appeared to act as either the inducers of apoptosis on human tumor cell lines or agents that alter the cell cycle and decrease the telomerase activity. Moreover, chemical species of this type possess Cu,Zn-superoxide dysmutase (SOD) mimicking properties.

The aim of this study was to synthesize a new series of copper complexes of ligands incorporating bidentate a-diimino moiety, such as 2-(imidazolin-2-yl)- (8, 10), 2-(tetrahydro-pirymidin-2-yl)- (9), 2-(oxazolin-2-yl)- (11), 2-(oxazin-2-yl)- (12, 13) and 2-(pirazin-2-yl)- (14) benzimidazoles.

Structures of the complexes obtained were confirmed by spectral (IR) data and C,H,N analysis. Important structural features were determined by X-ray crystallographic studies of compounds 12, 13 and 14 (Figure).

art.JPG

Figure. ORTEP drawings of complexes 12, 13 and 14.

2-(4,5-Dihydro-1H-imidazol-2-yl)-1H-benzimidazole CuCl2 (complex 8) showed a very potent Cu,Zn-SOD activity in vitro with IC50 of 0.09 µM, comparable to those described in the literature for best low molecular weight CuZnSOD mimics.

The in vitro biological tests against seven human cancer cell lines showed that the most active 2-(4,5-Dihydro-1H-imidazol-2-yl)-5-nitro-1H-benzimidazole CuCl2 (complex 10) possessed antitumor properties with IC50 of 4.76 - 10.84 µM, depending on the cell line.

 

Legal notice
  • Legal notice:
 

Related papers

Presentation: Poster at V Multidyscyplinarna Konferencja Nauki o Leku, by Ewa Dziemidowicz-Borys
See On-line Journal of V Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2006-01-25 18:07
Revised:   2009-06-07 00:44